Eddie Hickman
Stock Analyst at Guggenheim
(4.45)
# 284
Out of 5,126 analysts
20
Total ratings
68.42%
Success rate
20.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $12.73 | +174.94% | 4 | Feb 6, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $11 | $3.77 | +191.78% | 1 | Jan 20, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $64.62 | +34.63% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.43 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.60 | +155.81% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $15.17 | +111.01% | 1 | Mar 13, 2025 |
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $12.73
Upside: +174.94%
AtaiBeckley
Jan 20, 2026
Initiates: Buy
Price Target: $11
Current: $3.77
Upside: +191.78%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $64.62
Upside: +34.63%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.60
Upside: +155.81%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $15.17
Upside: +111.01%